Phathom Pharmaceuticals, Inc.
General ticker "PHAT" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $998.9M (TTM average)
Phathom Pharmaceuticals, Inc. does not follow the US Stock Market performance with the rate: -29.8%.
Estimated limits based on current volatility of 3.8%: low 7.07$, high 7.62$
Factors to consider:
- Earnings expected soon, date: 2026-10-29 bmo
- Total employees count: 371 (-13.1%) as of 2025
- Company does not operate outside US (retrieved using AI)
- Top business risk factors: Limited operating history, Dependence on VOQUEZNA, Need additional capital, Regulatory and compliance, Manufacturing disruptions
- Current price 40.0% below estimated low
- Earnings for 6 months up through Q2 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [11.53$, 27.85$]
- 2026-12-31 to 2027-12-31 estimated range: [8.98$, 22.26$]
Financial Metrics affecting the PHAT estimates:
- Negative: with PPE of -6.8 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: negative Operating cash flow
- Negative: negative Net income
- Negative: 4.56 < Interest expense per share per price, % of 5.40
- Negative: negative Industry operating income (median)
- Negative: Investing cash flow per share per price, % of -0.02 <= 2.08
Short-term PHAT quotes
Long-term PHAT plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.68MM | $55.25MM | $175.11MM |
| Operating Expenses | $167.99MM | $332.72MM | $335.10MM |
| Operating Income | $-167.31MM | $-277.47MM | $-159.99MM |
| Non-Operating Income | $-34.28MM | $-56.86MM | $-61.26MM |
| Interest Expense | $41.97MM | $72.01MM | $68.11MM |
| R&D Expense | $49.90MM | $34.08MM | $32.78MM |
| Income(Loss) | $-201.59MM | $-334.33MM | $-221.25MM |
| Net Income(Loss)* | $-201.59MM | $-334.33MM | $-221.25MM |
| Stockholders Equity | $-72.76MM | $-253.58MM | $-438.17MM |
| Inventory | $1.21MM | $3.21MM | $5.52MM |
| Assets | $413.84MM | $378.32MM | $259.15MM |
| Operating Cash Flow | $-137.58MM | $-266.77MM | $-166.78MM |
| Capital expenditure | $1.63MM | $0.14MM | $0.23MM |
| Investing Cash Flow | $-1.63MM | $-0.14MM | $-0.23MM |
| Financing Cash Flow | $367.58MM | $182.77MM | $-0.29MM |
| Earnings Per Share** | $-3.93 | $-5.29 | $-3.03 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.